GlassScriptPhysician profile
Robert Gregory Wooten
NPI 1922066232
$6,536.23
in general payments reported to CMS, 2019-2025
27 companies · $1,220 in 2025
The $1,220 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $584 · 2021: $677 · 2022: $1,013 · 2023: $961 · 2024: $904 · 2025: $1,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,085.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,011.44 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $809.62 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $694.90 | 2019-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $505.15 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $440.74 | 2019-2025 | Uzedy, Austedo Xr |
| Allergan, INC. | $376.53 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $280.94 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $242.67 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $187.75 | 2019-2022 | |
| Alkermes, INC. | $179.21 | 2019-2025 | Aristada, Vivitrol, Lybalvi |
| Ironshore Pharmaceuticals INC. | $158.32 | 2019-2023 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $147.04 | 2019-2025 | Fanapt |
| Eisai INC. | $77.86 | 2020 | |
| Lundbeck LLC | $73.09 | 2019-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $62.29 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $58.91 | 2019 | |
| Sun Pharmaceutical Industries INC. | $58.87 | 2020-2021 | |
| Axsome Therapeutics, INC. | $31.21 | 2025 | Auvelity |
| Neuronetics, INC. | $30.50 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $30.46 | 2019 | |
| Tris Pharma INC | $21.15 | 2023 | Dyanavel Xr |
| Livanova USA, INC. | $19.58 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Alfasigma USA, INC. | $13.96 | 2020 | |
| Corium, LLC | $12.10 | 2025 | Azstarys |
| Acadia Pharmaceuticals INC | $11.94 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wooten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.